JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Search

Novocure Ltd

Closed

SectorHealthcare

15.86 -6.65

Overview

Share price change

24h

Current

Min

15.77

Max

16.93

Key metrics

By Trading Economics

Income

13M

-24M

Sales

7.1M

174M

Profit margin

-14.052

Employees

1,605

EBITDA

-7.8M

-34M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+54.58% upside

Dividends

By Dow Jones

Next Earnings

23 Jul 2026

Market Stats

By TradingEconomics

Market Cap

216M

1.4B

Previous open

22.51

Previous close

15.86

News Sentiment

By Acuity

30%

70%

100 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Novocure Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

12 Feb 2026, 15:08 UTC

Hot Stocks

Stocks to Watch Thursday: Cisco, McDonald's, AppLovin -- WSJ

Peer Comparison

Price change

Novocure Ltd Forecast

Price Target

By TipRanks

54.58% upside

12 Months Forecast

Average 26.17 USD  54.58%

High 48 USD

Low 17 USD

Based on 6 Wall Street analysts offering 12 month price targets forNovocure Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

16.31 / 18.14Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

100 / 347 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat